New drug KR23343 enters first human safety trials
Knowledge-focused
Recruiting now
This early-stage trial tests the safety and tolerability of a new drug called KR23343 in 92 healthy adults aged 18 to 45. Participants receive either the drug or a placebo, and researchers monitor for side effects, lab changes, and how the drug moves through the body. The study a…
Phase: PHASE1 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC